Literature DB >> 28079544

Discontinuation of treatment and adverse events in an Italian cohort of patients on dolutegravir.

Paolo Bonfanti1, Giordano Madeddu, Roberto Gulminetti, Nicola Squillace, Giancarlo Orofino, Paola Vitiello, Stefano Rusconi, Benedetto M Celesia, Paolo Maggi, Elena Ricci.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28079544     DOI： 10.1097/QAD.0000000000001351

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study.

Authors:  Noelia Fernández-Bargiela; Sandra Rotea-Salvo; Luis Margusino-Framiñán; Vanesa Balboa-Barreiro; Isabel Martín-Herranz; Ángeles Castro-Iglesias; Álvaro Mena-De-Cea; Soledad López-Calvo; Pilar Vázquez-Rodríguez; Enrique Míguez-Rey; Purificación Cid-Silva
Journal:  Eur J Hosp Pharm       Date:  2020-10-13

2.  Reversibility of Central Nervous System Adverse Events in Course of Art.

Authors:  Lucia Taramasso; Giancarlo Orofino; Elena Ricci; Barbara Menzaghi; Giuseppe Vittorio De Socio; Nicola Squillace; Giordano Madeddu; Francesca Vichi; Benedetto Maurizio Celesia; Chiara Molteni; Federico Conti; Filippo Del Puente; Eleonora Sarchi; Goffredo Angioni; Antonio Cascio; Carmela Grosso; Giustino Parruti; Antonio Di Biagio; Paolo Bonfanti
Journal:  Viruses       Date:  2022-05-11       Impact factor: 5.818

3.  Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1.

Authors:  Hiroki Yagura; Dai Watanabe; Hiroyuki Kushida; Kosuke Tomishima; Hiroaki Togami; Atsushi Hirano; Masaaki Takahashi; Kazuyuki Hirota; Motoko Ikuma; Daisuke Kasai; Yasuharu Nishida; Munehiro Yoshino; Kunio Yamazaki; Tomoko Uehira; Takuma Shirasaka
Journal:  BMC Infect Dis       Date:  2017-09-16       Impact factor: 3.090

4.  Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study.

Authors:  Angella Namulindwa; John Hans Wasswa; Winnie Muyindike; Robert Tamukong; Joseph Oloro
Journal:  AIDS Res Ther       Date:  2022-04-02       Impact factor: 2.250

5.  A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.

Authors:  Pedro E Ferrer; Mark Bloch; Norman Roth; Robert Finlayson; David Baker; Ken Koh; David Orth; Rimgaile Urbaityte; Dannae Brown; Fraser Drummond
Journal:  Int J STD AIDS       Date:  2017-09-13       Impact factor: 1.359

6.  Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV.

Authors:  Lisa Van de Wijer; Wouter van der Heijden; Mike van Verseveld; Mihai Netea; Quirijn de Mast; Arnt Schellekens; André van der Ven
Journal:  AIDS Behav       Date:  2021-04-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.